RPL36P19

Across TCGA pan-cancer cohorts, RPL36P19 RNA is linked to patient survival in 13 of 34 cancer types, making it the most broadly survival-associated RPL36P19 data layer.

The strongest signal is observed in uveal melanoma (UVM), where higher RPL36P19 RNA is associated with worse overall survival. In most high-consensus cancer types, elevated RPL36P19 expression acts as an unfavorable survival marker, although some lineages such as BRCA and UCS show a favorable association.

UVM, THCA, and SKCM are the cancer types where RPL36P19 RNA most reproducibly stratifies survival.

RNA survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UVM	OS	Tertile	All	0.037	0.858	<.001	108	view →
THCA	OS	Tertile	All	0.910	0.996	<.001	84	view →
SKCM	DFS	Tertile	III,IV	0.232	0.676	<.001	57	view →
BLCA	OS	Tertile	IV	0.052	0.575	<.001	48	view →
PCPG	DFS	Tertile	All	0.466	0.805	<.001	33	view →
BRCA	OS	Tertile	All	0.705	0.559	.022	30	view →
ACC	DFS	Tertile	IV	0.010	0.383	<.001	27	view →
THYM	OS	Tertile	All	0.836	0.985	.015	24	view →
MESO	OS	Tertile	III,IV	0.239	0.608	.029	18	view →
LUAD	DFS	Tertile	IV	0.342	0.893	<.001	18	view →
UCS	OS	Tertile	III,IV	0.899	0.503	.040	12	view →
LUSC	DFS	Tertile	II,III,IV	0.138	0.390	.040	6	view →

Pink = unfavorable, green = favorable. Showing the 12 strongest of 13 lineages.

RPL36P19–UVM (OS)

Open the UVM breakdown →